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Epilepsy is one of the most common neurological disorders in 
human, with a prevalence of about 1% and a lifetime incidence of 
up to 3% [1]. 
The epilepsies present with a broad range of clinical features, and 
over 50 distinct epilepsy syndromes are now recognized. Seizure 
disorders can roughly be divided into idiopathic or symptomatic 
epilepsies. While symptomatic epilepsies are due to an identifiable 
cause such as metabolic disorders, brain trauma or intracranial 
tumors, idiopathic seizure disorders occur in the absence of 
identifiable causal factors and are thought to have a strong genetic 
contribution [1]. 
Idiopathic Generalized Epilepsy (IGE) is a group of disorders 
characterized by recurrent spontaneous seizures which onset 
simultaneously by both cerebral hemispheres in absence of 
detectable brain lesions or metabolic abnormalities. IGE has a 
prevalence of about 0.4% in the general population and constitutes 
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nearly one third of all epilepsies as well as the most common group 
of inherited seizures [2]. 
IGE syndromes usually start in childhood or adolescence, but some 
of them have adult onset. They manifest with typical absences, 
myoclonic jerks, and generalized tonic−clonic seizures, alone or in 
varying combinations and severity. Most seizures occur on 
awakening, particularly after sleep deprivation. 
Epidemiological studies indicate that genetic factors play a pivotal 
role in the etiology of IGE even though its mode of inheritance is 
complex. Recent progress in epilepsy research showed that IGE 
includes several single−gene traits showing Mendelian inheritance. 
A number of highly−penetrant genes have been localized or 
identified by studying large pedigrees through the classical 
approach based on linkage analysis and positional cloning. These 
studies led to the definition of novel clinical entities and to the 
recognition of neuronal ion−channel genes as major players in the 
genetics of IGE [3]. Mutations in genes encoding voltage−gated 
sodium channel subunits − SCN1A, SCN1B − and GABAA 
receptor subunits − GABRγ2 and GABRδ − have been identified in 
Genetic Epilepsy with Febrile Seizures plus (GEFS+) [4−7]. In 
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addition, mutations in genes encoding the α1 and β3 GABAA 
receptor subunits and voltage−gated calcium channel β4 subunit 
have been identified in families with IGE [8−10]. Ion channel genes 
are also involved in different familial forms of idiopathic focal 
epilepsy, including nocturnal frontal lobe epilepsy and benign 
neonatal and infantile seizures [11−15]. Taken together these 
findings provide evidence that primary defects in ion channels 
underlie epileptogenesis by altering the electrophysiological 
excitability of neuronal cell membranes and the communication 
between neurons [16]. Beside ion channel genes only few other 
specific pathophysiological pathways involved in IGE definitively 
emerged from genetic studies.  
Mutations in EFHC1 have been found in a proportion of families 
with autosomal dominant Juvenile Myoclonic Epilepsy (JME), a 
subtype of IGE [17] and is the most frequent cause of hereditary 
grand mal seizures. We previously mapped and narrowed a region 
associated with JME on chromosome 6p12-p11 (EJM1). EFHC1 
gene encodes a protein with an EF-hand motif, and mutations in 
EFHC1 cosegregate with epilepsy or EEG polyspike wave in 
affected members of unrelated families with JME [17]. Recently, 
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EFHC1  mutations have been shown to impair migration of cortical 
neuronal progenitors, suggesting a link between IGE and 
malformations of cortical development [18]. 
 A metabolic mechanism underlying idiopathic generalized epilepsy 
is suggested by the identification of mutations in the gene encoding 
the glucose transporter 1 (SLC2A1), in families affected by 
movement disorders and generalised epilepsy [19] and more 
recently in a proportion of patients with early onset idiopathic 
generalized epilepsy with absences, and in families with autosomal 
dominant idiopathic generalized epilepsies [20,21]. 
On the other hand the identification of susceptibility alleles 
involved in common sporadic forms of IGE has been proven 
difficult, most likely due to high degree of genetic heterogeneity. 
Indeed, affected sib−pairs and association studies led to the 
detection of several candidate loci, but none of hem found a 
clear−cut confirmation [22,23]. Thus, alternative approaches are 
required to dissect the complex genetics of IGE. 
The structural variation of the human genome is commanding a 
great deal of attention [24,25] as small, submicroscopic, genomic 
deletions and duplications (size 1 kb to 10 Mb) occur frequently 
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throughout the genome in healthy subjects. These Copy Number 
Variations (CNVs) result in the usual two copies of a gene changing 
to a single copy in a heterozygous deletion or more than two copies 
in duplications. Surprisingly, these submiscroscopic rearrangements 
often have no phenotypic expression, but they can act rare variants 
predisposing to complex diseases. In fact, they constitute up to 15% 
of all mutations underlying human monogenic diseases [26,27]. 
More recently it became evident that the CNVs and gene dosage 
effects could be also involved in the etiology of common 
neurological traits, well beyond rare mendelian disorders. In 
particular, some neurological diseases involved are 
Charcot−Marie−Tooth neuropathy type 1A [28], Smith−Magenis 
[29], Miller−Dieker [30], and Angelman syndromes [31]), such as 
autism spectrum disorders [32] and schizophrenia [33]. 
In idiopathic mental retardation, for instance, submicroscopic 
rearrangements are identified in about 5−10% of patients with 
otherwise normal cytogenetic analysis [34]. 
The role of microrearrangments in the pathogenesis of epilepsy has 
been initially recognized for complex syndromic epileptic 
phenotypes, leading to the definition of novel clinical entities, as 6q 
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terminal deletion syndrome, 15q24 microdeletion syndrome and a 
specific syndrome related to a genomic rearrangements of 17q12, 
associated with renal disease, diabetes, and epilepsy [35−37]. 
Many authors showed that genomic microdeletions are also 
common in different monogenic forms of epilepsy such as Severe 
Myoclonic Epilepsy of Infancy or Dravet syndrome (DS), [38], 
Lafora Disease [39] and BFNS (Benign Familial Neonatal Seizures) 
[40]. 
So far, the identification of CNVs underlying neurological diseases 
has been challenged by methodological limitations. 
CNVs are invisible on routine karyotyping, and classical 
cytogenetic techniques allow the genome−wide analysis of the 
entire genome but at low resolution and genomic aberrations below 
the resolution of about 10 Mb cannot be detected. Conversely, 
molecular techniques such as FISH and MLPA [41] allow the 
identification of small rearrangements but only at specific loci. 
Recent technology developments now enable the analysis of the 
entire human genome at high resolution and allow the efficient 
detection of novel disease−causing CNVs. 
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These techniques rely on the ability of synthesizing on a single slide 
(array) thousands of short oligonucleotides complementary to 
unique genomic sequences. CNVs are identified through a 
competitive hybridization between a test and control DNA 
(array−CGH) or by the typing of single nucleotide polymorphisms 
(SNP−array) [42]. 
Recently genome−wide surveys of genomic disorders led to the 
detection of microdeletions and then the identification of the 
causative genes STXBP1 and PCDH19 − for two epileptic 
encephalophaties, the Ohtahara syndrome and epilepsy in female 
patients with clinical findings compatible with Dravet syndrome, 
respectively [43,44].  
About idiopathic generalized epilepsy the most frequent of these 
CNVs identified to date is  the 15q13.3 microdeletion.  
It was first identified in 0.3% of patients with mental retardation, 
dysmorphic features and seizures. It then emerged that this same 
microdeletion occurs in 0.2% of patients with schizophrenia 
compared with 0.01% of controls. Finally, and with even higher 
frequency, the 15q13.3 microdeletion is present in 1% of patients 
with idiopathic generalized epilepsy [45]. It is observed in a range 
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of idiopathic generalized epilepsy subsyndromes including 
childhood absence epilepsy, juvenile myoclonic epilepsy, juvenile 
absence epilepsy and generalized tonic–clonic seizures alone [45]. 
Family studies reveal that the 15q13.3 microdeletion behaves as 
would be expected for a susceptibility variant; it is found in some 
but not all family members with idiopathic generalized epilepsy and 
some unaffected members also carry the copy number variant [45] 
The 1.5 Mb critical region spanned by 15q13.3 deletions harbours 7 
genes. Among these, CHRNA7 encoding the a7 subunit of the 
acetylcholine receptor represents the most plausible candidate for 
the seizure phenotype, as suggested by the involvement of α2, α4 
and β2 subunits of the same receptor in autosomal dominant 
nocturnal frontal lobe epilepsy [11−13]. 
In the same cohort of patients 15q11.2 and 16p13.11 deletions have 
been detected at 2−3 fold frequency than controls suggesting that 
these CNVs might also predispose to IGE [46]. 
Hence, the detection of a pathogenic CNV in a single patient or 
family affected by a genetic disorder may represent a critical step 
toward the identification of a disease gene and  high−density arrays 
now allow the genome−wide detection of CNVs sized less than 100 
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Kb. However, a number of studies indicate that CNVs are found at 
high frequency also in control populations, and most of them 
represent phenotypically neutral genomic variations [47]. 
Thus, the interpretation of a founded CNV, the biological 
consequences of genomic variations and their pathogenetic 
significance could be not easy. Furthermore, current data indicate 
that the etiology of IGE is highly heterogeneous and defined by 
several rare alleles with different penetrance and mode of 
inheritance. 
The search of genomic rearrangements in multiplex families 
showing a Mendelian pattern of inheritance circumvents the issue 
of statistical significance raised by linkage analysis and association 
studies and may represent a straightforward genetic approach to 
identify epilepsy genes in IGE and disclose novel important insights 
into the complex pathogenesis of this group of disorders and 
epileptogenesis. 
In this complex scenario we focused our CNV survey on candidate 
genes for IGE such as ion channels. In particular, we develop a 
specific experimental strategy to assess the role of DNA copy 
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number variations in familial idiopathic generalized epilepsy by 
array−CGH and to identify novel epilepsy genes.  
The study has a specific focus on ion channel genes, a large gene 
family with a key role in the regulation of neuronal excitability and 
epileptogenesis. 
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2 SUBJECTS AND METHODS 
2.1 Subjects 
2.1.1 Selection of patients with idiopathic generalized epilepsy 
We selected families affected by IGE through the Italian League 
against Epilepsy  (LICE)  network. 
Seizure types and epilepsy syndromes were classified according to 
International League Against Epilepsy (ILAE) definitions and 
classifications and subsequent revisions [48].  
In particular were selected patients affected by: 
-Childhood absences epilepsy;  
-Juvenile absences epilepsy; 
-Juvenile myoclonic epilepsy; 
-Generalized tonic-clonic seizures only/on awakening; 
-Generalized epilepsy with febrile seizures plus (GEFS+); 
 
All subjects were selected both prospectively or retrospectively. 
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Patients with neuropsychiatric diseases and/or mental retardation 
(according to DSM IV, 1994) were excluded, such as patients with 
brain structural anomalies and/or metabolic causes of epilepsy 
(symptomatic epilepsy). 
All patients were asked to participate in a study of epilepsy during 
routine clinical appointments at each site, in accordance with 
institutional standards and an informed written consent was 
obtained from patients or their legal representatives.  
 
We selected 160 multiplex families with at least two first−degree 
relatives or three relatives of different degree affected by IGE or 
GEFS+. 
 
All patients underwent accurate examination in each participating 
Center. 
Patients' evaluation included full details of clinical features of 
epilepsy, detailed familial and personal history with particular 
attention to the psychomotor development milestones or other 
significant pathologic conditions. The clinical evaluation include 
neurological examination and revision of neuroimaging studies. 
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For comparison, we used 165 control subjects from healthy blood 
donors (aged 40–60 years) related to Transfusion Center of the 
Giannina Gaslini Institute (Genoa, Italy). All subjects were 
surveyed through a structured questionnaire to exclude seizure 
disorders [49]. 
2.1.2 Collection and storage of biological samples 
Six to ten ml of peripheral blood was been collected from each 
patients and 1st degree family members and sent to Gaslini Institute 
for genomic DNA extraction. A database containaing information 
of each stored sample related to code number, personal data, 
diagnostic status, biological material and sending institution have 
been established according to the Oviedo Agreement 
recommendations, and in conformity to D.M. n.196/2003. 
So far are already available 580 DNA, including 160 familial cases 
and their relatives and 165 control subjects. 
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2.2 Methods 
2.2.1 Array−CGH assays 
For array−CGH we used the validated IonChannel CGH−Array, 
specifically designed for the detection of CNVs affecting 429 
candidate genes, according to the Gene Ontology (GO) Database. 
This array was been synthesized by Agilent on the basis of an our 
custom design. The proband of each family was been assayed by 
Array−CGH as follow: 500ng of purified DNA of a patient and of a 
control was been double−digested with RsaI and AluI for two hours 
at 37° degrees. Each digested sample was been labeled for two 
hours using Cy5−dUTP for the patient DNA and Cy3−dUTP for the 
control DNA. Labeled products was been columns purified and 
prepared according to the Agilent protocol. After probe 
denaturation and pre−annealing with 5ml of Cot−1 DNA, 
hybridization was been performed at 65° degrees with rotation for 
40 hours. After two washing steps the arrays was been analyzed 
with the Agilent scanner. Array−CGH data was been analyzed with 
a new R package we are currently developing. A beta version of 
this package − called TASSO, Tools for Automatic Segmentation 
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and Statistical significance Of array−CGH − has been already 
implemented and applied for the analysis of 60 array−CGH assay. 
We initially investigated genomic database to explore whether 
putative CNVs match polymorphic genomic variants. Then, 
validation of putative CNVs was been performed by Dye−reversal 
experiments with reciprocal labelling of the test and reference 
DNA. In addition, we tested by array−CGH the available family 
members to perform segregation analysis and assess the penetrance 
and clinical expressivity of the identified CNVs. 
To assess the impact of identified CNVs in IGE etiology we 
screened  additional 135 controls by Ion Channel CGH−Array and 
real−time quantitative PCR (Q−PCR).  
 
2.2.2 Statistical analysis and bioinformatics 
The TASSO package was been initially read the raw array-CGH 
data, preprocesses and normalizes them. The pre-processing step 
allows to detect and filter out poor quality spots. To accommodate 
poor quality flagged spots or missing information, the package 
provided an implementation of knn imputation [50]. In terms of 
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normalization, the package used a lowess fit to remove spurious and 
systematic intensity−dependent variations in the data. After 
normalization the log2−ratios of signal intensities of the sample and 
test was been sorted against the physical location of the probes on 
the genome. The segmentation algorithms included in our package 
will be SLM and CBS [50], while the calling step was achieved by 
FastCall, a novel procedure that aims to give aberration 
probabilities in a very fast and accurate way [50]. Once the analyses 
were completed, our package organized the results in a database 
and created an intuitive html interface that allowed the user to 
browse them. The interface included the following: a plot 
displaying the segmentation overlapped to the log2−ratio data [50]; 
a plot reporting FastCall results and the probability of aberration; 
the cytogenetic ideograms with predicted aberrations; a tabular 
summary of the predicted aberrations with link to UCSC and 
Genomic Variants databases; zooms of the genomic profile nearby 
the predicted aberrations. 
 
Sample power estimates were calculated assuming an α error of .05 
and a β error of 0.2 (ie, a power of 80%). Two-tailed unpaired t test 
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and Fisher exact tests were used for categorical sample and 
phenotype correlations; the nonparametric Mann-WhitneyU test 
was used to evaluate numerical data. 
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3 RESULTS 
We selected 160 families affected by IGE and collected 1576 DNA 
samples of the probands and available relatives. Among these, we 
collected 137 multiplex families accounting for 73 family members 
and for a 2,6 average number of affected individuals/family. 
 
We designed and tested a custom CGH−array specifically designed 
to explore 429 candidate genes at very high density (IonChannel 
array). 
Genes were been selected through the BIOMART tool 
(www.ensembl.org/biomart/martview) using the following GO IDs: 
GO:0015267 (channel activity), GO:0005326 (neurotransmitter 
transporter activity) and GO:0042625 (ATPase activity, coupled to 
transmembrane movement of ions). The initial list of genes was 
been manually elaborated to avoid redundancies, pseudogenes and 
genes with unclear genomic organization and inconsistent function. 
The final list of candidate genes includes 429 genes (Table 1). The 
array includes 60K probes covering the exons and introns of each 
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gene at the density of 100 bp and 1.000 bp, respectively. In 
addition, the array includes the 44K genome−wide probe set 
implemented in the widely used Agilent 44B commercial kit. Thus, 
the IonChannel array is expected to detect CNVs sized only few 
Kbs within the selected candidate genes. 
We initially tested the IonChannel array in control and aneuploidic 
DNA samples and analyzed the assay using the novel SLM 
algorithm implemented in the FastCall software e grouped into 24 
families, mostly involved in the transmembrane transport of ions 
(Table 1). Subsequently, we screened a first set of 137 cases 
affected by different familial forms of IGE and we identified these 
data: there are 68 patients (50%) with CNVs, and 69 patients (50%) 
without CNVs; of these 43 rearrangements are deletions and 266 
are duplications, and the deletion/duplication ratio is 0.16; the mean 
CNVs size in patients is 395, 939 Kb; of these, 5 patients have 
CNVs clearly pathogenic  (n=5), including 1 deletion and 4 
duplications (Table 2). Four out of five (80%) rearrangements 
involve genes we specifically selected for high resolution analysis 
(KCNE1, KCNE2, KCND2, GABRG2, TRPV2). Chromosome 21 
duplication affecting potassium channel genes KCNE1 and KCNE2 
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spans a polymorphic CNV. Two of these CNVs are intragenic and 
disrupt the genomic organization of a single ion channel gene, 
GABRG2 encoding the γ2 subunit of the GABAA receptor on 
chromosome 5 and KCND2 encoding the voltage−gated potassium 
channel Kv4.2 on chromosome 7 (Figure 1, 2). Segregation analysis 
in available family members showed that dup21, dup9 and dup17 
do not co−segregate with IGE. Intragenic CNVs affecting 
GABRG2 and KCND2 were also detected in the affected parents 
(Figure 3). 
Other 5 CNVs not co-segregate with IGE and are showed in Table 2 
and in Figure 4. 
These CNVs identified are not recurrent and sized is >50 Kb (range 
80 Kb-1.5 Mb)b. 
We also identified 29 small recurrent CNVs (recurrent in ≥2 
patients), showed in Table 3. They are 20 duplications and 9 
deletions, with  mean size 400 bp. Eighteen of these are not 
previously reported in Database of Genomic Variant and eight of 
these affecting interesting ion channel genes (KCND3, KCTD20, 
KCNH2, KVNJ6, KCNG2, GRM5, GRIK5, CACNA1A). 
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To assess the frequency of identified CNVs in ethnically−matched 
controls, we set−up TaqMan−based real−time assays. For each 
CNV we already tested 80−100 controls and found no positive 
individuals. 
In particular, in 165 healthy subjects  we identified: 74 subjects 
(45%) with CNVs and 91 subjects (55%) without CNVs; of these 
35 rearrangements are deletions and 186 are duplications, and the 
deletion/duplication ratio is 0.18; the mean CNVs size in healthy 
subjects is 404, 224 Kb. In particular, in 165 control subjects were 
not found the five not recurrent- rearrangements including 1 
deletion and 4 duplications found in patient with IGE (Table 2), as 
well as were not found the eight recurrent CNVs affecting ion 
channels showed in Table 3. 
The genomic data of 137 patients and 165 healthy subjects are 
summarized and compared in Table 4 and in Table 5. Statistical 
analysis failed to show any significant difference regarding the 
frequency (p=0.41), the type (deletion vs duplication; p=0.53) of 
the identified CNVs between patients and controls. 
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Statistical analysis showed a significant difference regarding gene-
enrichment, with an increased enrichment of ion channel genes in 
patients with IGE (p=0.0037) 
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4 DISCUSSION 
Epilepsy is one of the most common neurological conditions and 
for most patients (approximately 65%) with either generalized or 
partial epilepsies, the underlying cause is unknown and the 
condition is referred to as being ‘idiopathic’[1]. Overall, 30% of all 
individuals with epilepsy have idiopathic generalized epilepsy. In 
the past two decades an increasing number of mutations in genes 
predisposing for various forms of IGE have been identified [3]. 
Most of the mutations are found in genes encoding for voltage-or 
ligand-gated ion channels; they account for most familial forms of 
these disease [3] and so the IGE is  primarily a ‘channelopathy’.  
The role of copy number variation (CNVs) in intellectual disability, 
autism and  schizophrenia has been extensively investigated [32,33] 
and it has become increasingly clear that collectively rare variants 
contribute significantly to the genetic etiology of many neurological 
disorders, including epilepsy. In order to identify new genes that 
contribute to the genetic cause of epilepsy, we performed a high-
resolution screening of CNVs in 137 patients with idiopathic 
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generalized epilepsy. Our studies showed that CNVs affecting ion 
channel genes are a common finding in familial IGE. 
In particular, we identified a previously undescribed intragenic 
deletion on chromosome 5, affecting γ2 subunit of GABAA receptor 
(GABRG2), the major inhibitory neurotransmitter receptor in the 
Central Nervous System. The α1β2γ2S receptor is the most 
abundant receptor isoform and the γ2 subunit is critical for receptor 
trafficking, clustering and synaptic maintenance. To date, most 
GABAA receptors mutations associated with IGEs have been found 
in the γ2 subunit [51]. Phenotypes in the affected pedigrees are 
heterogeneous. Kang JQ et al [52] demonstrated that γ2 (Q351X) 
nonsense mutation, associated with genetic epilepsy with febrile 
seizures plus (GEFS+), had a dominant-negative effect on wild-type 
receptors by reducing their assembly, trafficking and surface 
expression. They supposed that this combination of loss of function 
and dominant-negative effect of the mutant subunits on the wild 
type subunits would result in considerable loss of inhibition and in 
associated GEFS+ phenotype. In other pedigrees the phenotype 
ranges from simple febrile seizures to the more severe seizures of 
the Dravet syndrome and Lanchance-Touchette et al. [51] reported 
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a family with a single point mutation P83S and a combination of 
febrile and childhood absence seizures. 
According to these data this is a strong candidate gene for epilepsy, 
because signalling through GABAA receptor provides almost all 
inhibitory tone to the brain, balancing the tendency of excitatory 
neuronal circuits to induce convulsions. So, the high degree of 
penetrance of rearrangement in our family, including and disrupting 
γ2 GABAA receptor subunit gene, can contribute to the occurrence 
of IGE in this family.  
 
The intragenic duplication disrupting the genomic organization of 
KCND2 in IGE is a novel intriguing finding and pinpoints a novel 
candidate gene for IGE. KCND2 encodes for a primary pore-
forming (α) subunit member within the Shal subfamily of voltage-
gated potassium channels, Kv4.2. Within the brain, Kv4.2  mediates  
a rapidly activating and inactivating (IA) Kv channels, contributing 
to action potential repolarization and repetitive firing, and affecting 
neuronal outputs [53]. In addition, somatodendritic IA channels 
modulate the back−propagation of action potentials in neuronal 
dendrites, and impact synaptic efficacy and plasticity [54]. 
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Recently, it has been reported that attenuation of IA has been linked 
to acquired experimental temporal lobe epilepsy [55] and a Kv4.2 
truncation mutant has been identified in a single patient with 
temporal lobe epilepsy [56].  
Hence, rearrangement  in our family, disrupting this physiologically 
important IA channel could lead to dysregulation of neuronal 
excitability, a hallmark of epilepsy. Our results suggests that 
KCND2 may segregate within pedigrees and may suggest that 
KCND2 may have a significant role in the etiology of IGE. The 
other CNVs do not segregate within pedigrees and may not be 
readily interpreted without further genetic and functional studies. 
However, CNV including  KCNV2 gene is interesting. Kcnv2 
encodes the voltage-gated potassium channel Kv8.2, which is a 
silent subunit as a homotetramer. Kv8.2 can form functional 
heterotetramers with Kv2 subunits and influence membrane 
translocation and channel properties [57]. Members of the Kv2 
family are expressed in the nervous system and underlie the 
neuronal delayed rectifier K+ current, which is important for 
limiting membrane excitability, particularly under conditions of 
repetitive stimulation [57]. In the hippocampus, which is a region of 
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particular importance for seizure generation, Kv2.1 is the major 
contributor to the delayed rectifier potassium current and 
colocalizes with Kv8.2 in hippocampal pyramidal neurons. 
Jorge BS et al [57] evaluated the in vivo effect of Kcnv2 variants in 
transgenic mice and, to determine whether the human ortholog 
contributes to human epilepsy, they screened epilepsy patients for 
genetic variation in KCNV2. They demonstrated that Kcnv2 
transgene-mediates transfer of seizure susceptibility in mice, as well 
as human variants that alter delayed rectifier K+ currents. 
According to these authors, we propose KCNV2 as an epilepsy 
gene in humans.  
We also identified 29 small  recurrent CNVs. Eight of these are not 
previously reported in DGV and affect interesting ion channel 
genes (KCND3, KCTD20, KCNH2, KVNJ6, KCNG2, GRM5, 
GRIK5, CACNA1A). 
CACNA1A mutations are associated to epilepsy with absences 
[58], and mutation in KCNJ6, encoding for GIRK 2 (Kir3.2), a G-
protein-coupled inwardly rectifying K+ channel, have previously 
found to be associated with epilepsy both in mice and humans, 
above all in patient with juvenile myoclonic epilepsy [59]; KCND3 
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and KCNH2 encodes for ion channels involved in Brugada 
syndrome and long QT, both diseases perhaps linked to sudden 
death in epilepsy (SUDEP) [60,61]. 
 
Based on these findings these genes can be regarded as a common 
cause of epilepsy or allelic susceptibility  to epilepsy, even if more 
comprehensive investigations will be needed to clarify the role of 
these ion channels in epilepsy. We showed that the cumulative 
incidence of rare CNVs is not significantly higher in patients with 
familial IGE and the type (deletions vs duplications) is not 
significantly different in patients with familial IGE and in healthy 
subjects. However, the number of genes involved in CNVs and the 
type of ion channel represent key factors underlying pathogenesis. 
In our study, a significant enrichment of genes is observed within 
CNVs identified in IGE patients. Particularly, CNVs including 
KCND2, GABRG2, inherited from an affected parent, have not 
been found in healthy subjects; recurrent CNVs affecting  KCND3, 
KCNH2, KVNJ6, CACNA1A genes have not been found in healthy 
subjects. The same, rare not co-segregating CNVs are found only in 
IGE patients, even if inherited from an unaffected parent.  
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Moreover, rearrangements inherited from a healthy parent cannot 
always be considered a benign variation. Indeed, it already was 
demonstrated that CNVs may represent susceptibility alleles for a 
number of neuropsychiatric disorders, including idiopathic epilepsy 
[45].  
Then, it should be emphasized that CNVs detection is largely 
dependent on the type of platform (array-CGH vs. single-nucleotide 
polymorphism genotyping), the density and design of the array, and 
the setting of analytic parameters [62]. Most population-based CNV 
surveys have been performed by single-nucleotide polymorphism 
arrays, whereas array-CGH has become the elective routine 
diagnostic tool to identify genomic rearrangements in patients [62]. 
We identified 5 previously unreported segregating within pedigrees 
CNVs in IGE patients, indicating that recurrent polymorphic CNVs 
may have been missed by large scale population single-nucleotide 
polymorphism–based studies. Accordingly, CNVs screening should 
include appropriate internal controls, and heterogeneous data from a 
public database such as the Database of Genomic Variants should 
be considered with caution within a diagnostic context. 
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5 CONCLUSIONS 
Our study confirm that impairment of neuronal ion currents 
represents a common pathophysiological mechanism in 
epileptogenesis. In particular, we identified 2 epilepsy-genes 
(KCND2, GABRG2) and 8 susceptibility-epilepsy genes (KCND3, 
KCTD20, KCNH2, KVNJ6, KCNG2, GRM5, GRIK5, 
CACNA1A). The custom  CGH- array  specifically designed to 
explore candidate genes encoding  ion channels at very high density 
(IonChannel array) should be useful for other channalopathies 
(cardiac, neuromuscular, endocrinological and other neurological 
diseases). In addition, the characterization of a novel channels 
involved in epilepsy will define a biological target for the 
development of new antiepileptic drugs. 
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TRANSIENT RECEPTOR CHANNELS 21
PURINERGIC RECEPTOR CHANNELS 7
CYCLIC NUCLEOTIDE CHANNELS 6

















Pt. ID RESULTS SIZE GENE(S)
E15 dup21 34.625.253 34.887.912 262.659 KCNE1, KCNE2
I15 dup7 119.153.841 119.807.574 653.733 KCND2
I31 del5 161.446.702 161.964.455 517.753 GABRG2


















I72  dup9p 2.706.657 2.822.700 116 KCNV2











I120 del9q 72.418.491 72.717.377 299.378 TRPM3
I124  dup18q 22.289.206 22.350.197 158.507 KCTD1
BREAKPOINTS' LOCATION (bp)
 
Table 2 Genetic details of CNVs identified by IonChannel array 
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region (bp) Call type
Intron /       
Exon
Recurrent 
probe set CNV Genes
V27-1Q 6 5 36518172 36518583 411 GAIN E KCND20
V8-1Q 6 4 36518348 36518583 235 GAIN E KCND20
V31-1Q 6 4 36518348 36518583 235 GAIN E KCND20
V28-2Q 6 4 36518348 36518583 235 GAIN E KCND20
V27-2Q 6 4 36518348 36518583 235 GAIN E KCND20
V25-1Q 6 4 36518348 36518583 235 GAIN E KCND20
V24-1Q 6 4 36518348 36518583 235 GAIN E KCND20
V23-1Q 6 4 36518348 36518583 235 GAIN E KCND20
V21-2Q 6 4 36518348 36518583 235 GAIN E KCND20
V14-2Q 6 4 36518348 36518583 235 GAIN E KCND20
V8-1Q 7 3 150302727 150303488 761 GAIN I/E KCNH2
V14-2Q 7 3 150302727 150303488 761 GAIN I/E KCNH2
V10-2Q 10 10 50490334 50492169 1840 GAIN I/E
CHAT/SLC1
8A3
V08-2Q 10 8 50491175 50492169 994 GAIN I/E CHAT
V8-1Q 11 5 87881702 87882547 845 GAIN I/E GRM5
V25-1Q 11 5 87881702 87882547 845 GAIN I/E GRM5
V24-1Q 11 5 87881702 87882547 845 GAIN I/E GRM5
V14-2Q 11 5 87881702 87882547 845 GAIN I/E GRM5
V12-1Q 19 6 13179721 13181315 1590 GAIN I/E CACNA1A
V15-2Q 19 3 13180475 13181315 840 GAIN I/E CACNA1A








region (bp) Call type
Intron /       
Exon
Recurrent 
probe set CNV Genes
V30-1Q 1 3 112332967 112333041 74 LOSS I/E KCND3
V27-2Q 1 3 112332967 112333041 74 LOSS I/E KCND3
V31-1Q 8 3 106883442 107377047 494000 LOSS I/E
ZFPM2/OXR
1
V25-1Q 8 3 106883442 107377047 494000 LOSS I/E
ZFPM2/OXR
1
V24-1Q 8 3 106883442 107377047 494000 LOSS I/E
ZFPM2/OXR
1
V14-2Q 10 3 87370129 87371814 1680 LOSS I GRID1
V10-2Q 10 3 87370129 87371814 1680 LOSS I GRID1
V37-2Q 21 9 38076596 38081637 5040 LOSS I KCNJ6











Table 3 Recurrent CNVs in 137 pts with IGE 
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  CNVs no CNVs TOTAL 
Cases 68 69 137 
Controls 74 91 165 
Total 142 160 302 
Table 4 n° CNVs in cases vs controls; p > 0.05 
 
 
  DELETIONS DUPLICATIONS TOTAL 
Cases 43 266 309 
Controls 35 186 221 
Total 78 452 530 




Figure 1 CGH-array in family ID I31. It showed a del5q, spanning 




Figure 2 CGH-array in family ID I15. It showed a dup7q, spanning 




Figure 3 Segregation analysis of identified CNVs (1/2) 
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Figure 4 Segregation analysis of identified CNVs (2/2) 
